Rankings
▼
Calendar
TNGX FY 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TNGX
Tango Therapeutics, Inc.
$2B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$62M
+48.3% YoY
Gross Profit
$0
0.0% margin
Operating Income
-$111M
-178.4% margin
Net Income
-$102M
-162.9% margin
EPS (Diluted)
$-0.87
Cash Flow
Operating Cash Flow
-$139M
Free Cash Flow
-$140M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$399M
Total Liabilities
$53M
Stockholders' Equity
$346M
Cash & Equivalents
$112M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$62M
$42M
+48.3%
Gross Profit
$0
$42M
-100.0%
Operating Income
-$111M
-$146M
+23.6%
Net Income
-$102M
-$130M
+22.0%
← Q4 2024
All Quarters
Q1 2025 →